CN106466482A - A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof - Google Patents
A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof Download PDFInfo
- Publication number
- CN106466482A CN106466482A CN201510514121.2A CN201510514121A CN106466482A CN 106466482 A CN106466482 A CN 106466482A CN 201510514121 A CN201510514121 A CN 201510514121A CN 106466482 A CN106466482 A CN 106466482A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- kinds
- acid
- treatment
- mixed above
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to compositionss of a kind of prevention, treatment or suppression membrane disease and preparation method thereof, this compositionss can be liquid preparation or semi-solid preparation form, and said composition contains following weight ratio ingredient：Antimicrobial 0.001%～35.0%, analgesics 0～10.0%, bioadhesive polymer 0.001%～20.0%, wetting agent 0～30.0%, pH adjusting agent 0～5.0%, correctivess 0～8.0%, emulsifying agent 0～5.0%, assist antimicrobial 0～8.0%.The present composition is applied to skin, mucous membrane surface, play prevention and treatment membrane disease or disease, the resident medicine-feeding part of this compositionss, discharge antimicrobial and can effectively kill harmful microorganism, this compositionss have bioadhesive simultaneously, keep resting on for a long time medicine-feeding part, isolate microorganism infection, prevent superinfection, accelerate the effect of wound healing.
Description
Technical field
The present invention relates to compositionss of a kind of prevention, treatment or suppression membrane disease or symptom and preparation method thereof, this group
Compound can be liquid preparation or semi-solid preparation form, is applied to skin, mucous membrane surface using this compositionss, such as oral cavity,
Nasal cavity, gastrointestinal tract and respiratory tract, vagina, bladder, genitals, epidermis etc., play prevention and treatment membrane disease or disease,
Including ulcer, inflammation, traumatic damage or corrosivity damage, microbial infection etc., such as oral ulcer (aphtha), herpes labialis,
Radiotherapy skin ulcer, reproductive tract ulcer, gastric mucosa ulcer, intestinal mucosa ulcer, actinic keratosises, behcet's syndrome,
Wart, halitosis, gingival swelling and pain etc.；Using the resident medicine-feeding part of this compositionss, discharging antimicrobial can effectively kill
Do harm to microorganism, this compositionss have bioadhesive simultaneously, keep resting on for a long time medicine-feeding part, isolate microorganism infection,
Prevent superinfection, accelerate the effect of wound healing.
Background technology
Membrane disease is belonging to ulcer, inflammation, traumatic damage or corrosivity and damages class disease or disease, including oral cavity
Ulcer (aphtha), herpes labialis, radiotherapy skin ulcer, reproductive tract ulcer, gastric mucosa ulcer, intestinal mucosa ulcer, light
The property one of which such as keratosiss, behcet's syndrome, wart, halitosis, gingival swelling and pain or more than two kinds diseases or disease.
Oral disease is a kind of common frequently-occurring disease, and sickness rate is high, very big to human health damage, but often not
Paid attention to by extensive patients.Its main pathogenic factor of oral disease is to lead to a large amount of pathogenic bacterium due to the accumulation of Yin Yuan area dental plaque
Breeding, caused by its bacteriotoxin discharging and metabolite damage to periodontal, gingiva.Common oral disease have gingivitiss,
Oral mucositis, pharyngitis etc., sickness rate in crowd for the oral disease is very high, and almost everyone has oral problem, and 60%
The crowd of left and right suffers from different degrees of oral ulcer, halitosis, pharyngitis, and obstinate recurrent oral ulceration reaches 10% about,
Particularly after oral cavity, nasopharynx and periodontal surgery；Radiotherapy chemotherapy, Pneumology Department, contagious department patient and oral transmucosal intubation disease.
Oral ulcer is recurrent aphtha (recurrent aphthous ulcer, RAU), also known as recurrent mouth
Skin ulcer, recurrent oral ulceration (recurrent oral ulceration, ROU), recurrent aphthous stomatitiss (recurrent
Aphthous stomaitis), it is a kind of disease of sickness rate highest in the disease of cari oris mucosa.Its pathogenesis is still indefinite,
May there is relation with digestive system function disorder, cryptorrhea, the mental status, inherited genetic factorss etc..In addition, cancer patient exists
When carrying out chemicotherapy treatment, the toxicity of its induction is also the key factor leading to oral ulcer, according to data report, head-cervical radiotherapy
In patient, the incidence rate of oral ulcer is 85%-100%, and the sickness rate oral ulcer after chemotherapy is up to 50%-90%.Clinical table
Now be mainly erythroplakia of oral mucosa, edema, ulcer and necrosis, pain, infection can be caused, thus quality of life to patient and
The compliance for the treatment of produces and has a strong impact on, and even results in the interruption for the treatment of plan.
Limit mucositiss degree at present and control the measure of symptom to be broadly divided into laser therapy, Drug therapy and mouth care,
For mitigation symptoms, promote healing.But can thorough anti-treating dental ulcer still without generally acknowledged measure.
Periodontal disease is a kind of common oral disease occurring in periodontal tissue, be by Periodontal Pathogens (as viscous Actinobacillus,
Porphyromonas gingivalis, Streptococcus mutans, staphylococcus aureuses, Candida albicans etc.), non-pathogenic bacteria and wound etc. draw
Rise, may occur in which the symptoms such as dental plaque, periodontal abscess, pain, bleeding, halitosis and odontoseisiies, be broadly divided into gingivitiss, tooth
Zhou Yan, periodontal trauma and periodontal atrophy etc..
The research of domestic associated mucosal drug-delivery preparation, is primarily directed to antiinflammatory antiallergic agent ammonia and carrys out the medicine that cluck promise is designed
Preparation, such as patent publication No. are the Chinese invention of CN1850059A, CN102429893A；It is mainly pin in terms of the rinsing the mouth of oral cavity
The pharmaceutical preparation that glucose sugar chlorhexidine, Chinese herbal medicine extracting composition antimicrobial are designed, as patent publication No. is
The Chinese invention of CN102335102A, CN103446027A.Advantage of the present invention using the resident medicine-feeding part of this compositionss,
Discharge antimicrobial and can effectively kill harmful microorganism, this compositionss have bioadhesive simultaneously, keep long-time
Rest on medicine-feeding part, isolate microorganism infection, prevent superinfection, accelerate the effect of wound healing.
Content of the invention
The technical problem to be solved in the present invention be provide a kind of prevention, treatment or suppression membrane disease or symptom compositionss and
Its preparation method.The each composition of compositionss can be warm well, product is stable, can have antibacterial, isolation, analgesia, moisturizing concurrently
Function.Using the resident medicine-feeding part of this compositionss, discharge antimicrobial and can effectively kill harmful microorganism, simultaneously this
Plant compositionss and there is bioadhesive, keep resting on for a long time medicine-feeding part, isolate microorganism infection, prevent superinfection,
Accelerate the effect of wound healing, be particularly well-suited to oral cavity, nasal cavity, gastrointestinal tract and respiratory tract, vagina, bladder, genitals, table
The position such as skin membrane disease.
Compositionss and preparation method thereof of prevention, treatment or suppression membrane disease a kind of are it is characterised in that described
The component of compositionss and weight percent content are：
Heretofore described membrane disease is belonging to ulcer, inflammation, traumatic damage or corrosivity damage class disease or
Disease, including oral ulcer (aphtha), herpes labialis, radiotherapy skin ulcer, reproductive tract ulcer, gastric mucosa ulcer, intestinal
The one of which such as mucosal ulcer, actinic keratosises, behcet's syndrome, wart, halitosis, gingival swelling and pain or more than two kinds diseases
Disease or disease；
In the present invention, compositionss can be solution, gel, gum, spray, gargarism, emulsion agent, ointment
The form of agent；Preferably composition forms are solution, spray, gargarism, emulsion agent；Optimal set solvate form be solution,
Spray, gargarism.
Heretofore described antimicrobial be glucose chlorhexidine, chlorhexidine acetate, benzalkonium chloride, benzethonium chloride,
Cetrimonium bromide, poly (hexamethylene), cetylpyridinium chloride, brocide, parachlorometaxylenol, 2,
4,4 '-three chloro- 2 '-dihydroxy diphenyl ethers, povidone iodine, phenol derivativess, glucoseoxidase, lysozyme, hydrogen peroxide, mistake
One of which or two kinds of things mixed above such as oxidation urea, xylitol；Preferably antimicrobial is chosen as glucose chlorhexidine, acetic acid
Chlorhexidine, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, 2,4,4 '-three chloro- 2 '-dihydroxy diphenyl ethers, povidone iodine,
The one of which such as glucoseoxidase, lysozyme, xylitol or two kinds of things mixed above；Optimum antimicrobial is chosen as Fructus Vitis viniferae
Sugared chlorhexidine, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, 2,4,4 '-three chloro- 2 '-dihydroxy diphenyl ethers, glucose
The one of which such as oxidase, lysozyme, xylitol or two kinds of things mixed above.
The preferable consumption of heretofore described antimicrobial is 0.01%～10.0%, and optimum consumption is 0.1%～5.0%.
Heretofore described analgesics are cincaine, lignocaine, benzocaine, procaine, tetracaine, first
The one of which such as piperazine caine, cocaine, dyclonine, benzyl alcohol, benzoic acid or two kinds of things mixed above；Preferably analgesics choosing
Select is the one of which such as lignocaine, procaine, benzyl alcohol, benzoic acid or two kinds of things mixed above；Optimum analgesics are benzene
Methanol.
The preferable consumption of heretofore described analgesics is 0.001%～5.0%, and optimum consumption is 0.1%～3.0%.
Heretofore described bioadhesive polymer is Carbomer, hyetellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose
Element, sodium carboxymethyl cellulose, poly- sodium propionate, sodium alginate, carboxymethyl chitosan, hydroxypropyl chitosan, lactate shitosan,
Fucose, oligochitosan, hyaluronic acid, Aloe glue, tragacanth, xanthan gum, carrageenan, Polyvinylpyrrolidone etc. wherein one
Plant or two kinds of things mixed above；Preferably bioadhesive polymer is Carbomer, hyetellose, hydroxypropyl methylcellulose, carboxymethyl fibre
The plain sodium of dimension, poly- sodium propionate, sodium alginate, Aloe glue, carboxymethyl chitosan, hydroxypropyl chitosan, lactate shitosan, thoroughly
One of which or two kinds of things mixed above such as bright matter acid sodium, Polyvinylpyrrolidone；Optimum bioadhesive polymer is Carbomer, hydroxyl second
The one of which such as cellulose, hydroxypropyl chitosan, hyaluronate sodium, sodium carboxymethyl cellulose, polypropylene sodium or more than two kinds mix
Compound.
The preferable consumption of heretofore described bioadhesive polymer is 0.01%～10.0%, and optimum consumption is 0.1%～5.0%.
Heretofore described wetting agent be glycerol, Polyethylene Glycol, propylene glycol, erythritol, Sorbitol, Mannitol,
The one of which such as maltose alcohol, collagen protein or two kinds of things mixed above；Preferably wetting agent select be glycerol, Polyethylene Glycol, third
The one of which such as glycol, collagen protein, Sorbitol or two kinds of things mixed above；It is glycerol, poly- second two that optimum wetting agent selects
The one of which such as alcohol, collagen protein, Sorbitol or two kinds of things mixed above.
The preferable consumption of heretofore described wetting agent is 0.01%～15.0%, and optimum consumption is 0.5%～5.0%.
Heretofore described pH adjusting agent is tartaric acid, malic acid, citric acid, 1-Hydroxy-1,2,3-propanetricarboxylic acid., phosphoric acid, lactic acid, essence
Propylhomoserin, sodium hydroxide, potassium hydroxide, triethanolamine, diisopropanolamine (DIPA), triisopropanolamine, trometamol, amino methyl third
The one of which such as alcohol, tetrahydroxypropyl ethylenediamine or two kinds of things mixed above；Preferably pH adjusting agent selects is tartaric acid, Fructus Mali pumilae
Acid, citric acid, phosphoric acid, lactic acid, arginine, sodium hydroxide, potassium hydroxide, triethanolamine, trometamol, amino methyl
The one of which such as propanol or two kinds of things mixed above；It is tartaric acid, citric acid, lactic acid, hydroxide that optimum pH adjusting agent selects
The one of which such as sodium, potassium hydroxide, triethanolamine, trometamol, aminomethylpropanol or two kinds of things mixed above.
Heretofore described flavoring agent is saccharin sodium, steviosin, cyclamate, Sucralose, Sorbitol, menthol, wood
The one of which such as sugar alcohol or two kinds of things mixed above；Preferably flavoring agent select be saccharin sodium, steviosin, Sucralose, Sorbitol,
The one of which such as xylitol or two kinds of things mixed above；It is steviosin, Sorbitol, xylitol etc. wherein that optimum flavoring agent selects
Plant or two kinds of things mixed above.
Heretofore described emulsifying agent is Polysorbate, sodium laurylsulfate, glyceryl monostearate, polyoxyethylene groups castor
The one of which such as Oleum Sesami derivant or two kinds of things mixed above；Preferably emulsifying agent is that Polysorbate, polyoxyethylene groups Oleum Ricini derive
The one of which such as thing or two kinds of things mixed above；Optimum emulsifying agent selects to be that polysorbate 60, polyoxyethylene groups Oleum Ricini derive
The one of which such as thing or two kinds of things mixed above；
Heretofore described auxiliary antimicrobial is imidazolidinyl urea, interior uride, iodopropynyl formic acid fourth
The one of which such as fat, benzylalcohol, benzoic acid, potassium sorbate, phenoxyethanol, parabenses or two kinds of things mixed above；Preferably
Auxiliary antimicrobial selects to be imidazolidinyl urea, iodopropynyl formate butyl, potassium sorbate, phenoxyethanol, Ni Bo
The one of which such as golden esters or two kinds of things mixed above；It is iodopropynyl formate butyl, Buddhist nun that optimum antimicrobial selects
One of which or two kinds of things mixed above such as the golden esters of pool, potassium sorbate.
Inventor on the basis of scheme presented above, according to compound mode provided by the present invention, further
Provide following preferred version.
In above-mentioned priority scheme, each composition is preferably：Antimicrobial can be glucose chlorhexidine, benzalkonium chloride,
Benzethonium chloride, cetylpyridinium chloride, 2,4,4 '-three chloro- 2 '-dihydroxy diphenyl ethers, glucoseoxidase, lysozyme etc. are wherein
One or two or more kinds mixture；Analgesics can be the one of which such as lignocaine, procaine, benzyl alcohol, benzoic acid or
Two kinds of things mixed above；Bioadhesive polymer can be Carbomer, hyetellose, hydroxypropyl chitosan, hyaluronate sodium, carboxylic
The one of which such as sodium carboxymethylcellulose pyce, polypropylene sodium or two kinds of things mixed above；
Wetting agent can be the one of which such as glycerol, Polyethylene Glycol, collagen protein, Sorbitol or two kinds of things mixed above；PH adjusts
Section agent can be tartaric acid, citric acid, lactic acid, sodium hydroxide, potassium hydroxide, triethanolamine, trometamol, amino methyl
Propanol；Flavoring agent can be the one of which such as saccharin sodium, steviosin, Sucralose, Sorbitol, xylitol or two kinds mixed above
Thing；Emulsifying agent can be the one of which such as polysorbate 60, polyoxyethylene groups castor oil derivative or two kinds of things mixed above；
Auxiliary antimicrobial can be imidazolidinyl urea, iodopropynyl formate butyl, potassium sorbate, phenoxyethanol, Ni Bo
The one of which such as golden esters or two kinds of things mixed above.
The preparation method of the present composition is：
(1) dissolve：Take bioadhesive polymer, plus suitable quantity of water, heating, it is stirred continuously and makes dissolving, obtain solution A, standby；
Go bail for humectant, microorganism agent, assist antimicrobial, emulsifying agent, analgesics, plus suitable quantity of water, be stirred continuously and make dissolving, obtain
Solution B, standby；Take correctivess, plus suitable quantity of water, it is stirred continuously and makes dissolving, obtain solution C, standby；Take pH adjusting agent,
Plus suitable quantity of water, it is stirred continuously and makes dissolving, obtain solution D.
(2) allocate：In solution A, add solution B, stir evenly；Add solution C, stir evenly；Add solution D, stir evenly,
Use suitable quantity of water constant volume, obtain final product.
Specific embodiment
Embodiment one
Compositionss and preparation method thereof of prevention, treatment or suppression membrane disease a kind of are it is characterised in that described compositionss
Constituent content：
System stability：System is the viscous liquid of single stable, in 37 DEG C ± 2 DEG C of temperature, relative humidity 75% ± 5%
Under conditions of place the items quality index no significant change of 3 months test samples.
Killing microorganisms effect：According to《Disinfection technology standard》Detection method, stock solution act on 1min, to golden yellow Portugal
Grape coccus and escherichia coli kill the equal ＞ of logarithm value 6.00；Stock solution acts on 1min, kills the equal ＞ of logarithm value to Candida albicans
6.00.Experiment shows oral cavity pathogen is had good killing action.
Biological assessment：
Cell toxicity test is carried out to embodiment one compositionss using mtt assay, has been come with cell relative growth rate (RGR)
Judge cytotoxicity grade, its cytotoxicity of result is 1 grade, is qualified.
Embodiment one compositionss lixiviating solution is injected in the Intradermal of test rabbit, 24h, 48h and 72h after injection, perusal
Test rabbit all has no erythema, edema and necrosis phenomena, and this is to animal body no Intradermal irritant reaction.
With albino guinea-pig as animal subject, (GPMT) is tested using maximal dose, by the lixiviating solution note of embodiment one compositionss
Penetrate in Cavia porcelluss Intradermal, after carrying out Intradermal induction, stick in induction period not test (N.T.) position local and excited, divide in different time
The skin conditions at position Guan Cha not excited by Cavia porcelluss, with Magnusson and Kligman grade scale to each position and every of exciting
The skin erythema of one observing time and edema reaction are classified.Erythema and edema in result, and sensitization test (STT) is feminine gender, table
Bright embodiment one compositionss are to animal body no sensitivity response.
Using the sodium chloride lixiviating solution of embodiment one compositionss and vegetable oil lixiviating solution as test group, inject respectively with matched group
In Mice, and the general state in 4h, 24h, 48h, 72h observation and record test group and matched group, toxicity performance
With dead animal number.Result shows, immediate reaction, 4h, 24h, 48h, 72h observe avirulence symptoms, and body weight is not yet
Decline, the no Acute systemic toxicity reaction of embodiment one compositionss is described.
Embodiment two
Compositionss and preparation method thereof of prevention, treatment or suppression membrane disease a kind of are it is characterised in that described compositionss
Constituent content：
System stability：System is the viscous liquid of single stable, in 37 DEG C ± 2 DEG C of temperature, relative humidity 75% ± 5%
Under conditions of place the items quality index no significant change of 3 months test samples.
Killing microorganisms effect：According to《Disinfection technology standard》Detection method, stock solution act on 3min, to golden yellow Portugal
Grape coccus and escherichia coli kill the equal ＞ of logarithm value 3.00；Stock solution acts on 3min, kills the equal ＞ of logarithm value 3.00 to Candida albicans.
Experiment shows oral cavity pathogen is had good killing action.
Biological assessment：
Cell toxicity test is carried out to embodiment two compositionss using mtt assay, has been come with cell relative growth rate (RGR)
Judge cytotoxicity grade, its cytotoxicity of result is 1 grade, is qualified.
Embodiment two compositionss lixiviating solution is injected in the Intradermal of test rabbit, 24h, 48h and 72h after injection, perusal
Test rabbit all has no erythema, edema and necrosis phenomena, and this is to animal body no Intradermal irritant reaction.
With albino guinea-pig as animal subject, (GPMT) is tested using maximal dose, by the lixiviating solution note of embodiment two compositionss
Penetrate in Cavia porcelluss Intradermal, after carrying out Intradermal induction, stick in induction period not test (N.T.) position local and excited, divide in different time
The skin conditions at position Guan Cha not excited by Cavia porcelluss, with Magnusson and Kligman grade scale to each position and every of exciting
The skin erythema of one observing time and edema reaction are classified.Erythema and edema in result, and sensitization test (STT) is feminine gender, table
Bright embodiment two compositionss are to animal body no sensitivity response.
Using the sodium chloride lixiviating solution of embodiment two compositionss and vegetable oil lixiviating solution as test group, inject respectively with matched group
In Mice, and the general state in 4h, 24h, 48h, 72h observation and record test group and matched group, toxicity performance
With dead animal number.Result shows, immediate reaction, 4h, 24h, 48h, 72h observe avirulence symptoms, and body weight is not yet
Decline, the no Acute systemic toxicity reaction of embodiment two compositionss is described.
Embodiment three
Compositionss and preparation method thereof of prevention, treatment or suppression membrane disease a kind of are it is characterised in that described compositionss
Constituent content：
System stability：System is the viscous liquid of single stable, in 37 DEG C ± 2 DEG C of temperature, relative humidity 75% ± 5%
Under conditions of place the items quality index no significant change of 3 months test samples.
Killing microorganisms effect：According to《Disinfection technology standard》Detection method, stock solution act on 1min, to golden yellow Portugal
Grape coccus and escherichia coli kill the equal ＞ of logarithm value 3.00；Stock solution acts on 1min, kills the equal ＞ of logarithm value to Candida albicans
3.00.Experiment shows oral cavity pathogen is had good killing action.
Biological assessment：
Cell toxicity test is carried out to embodiment three compositionss using mtt assay, has been come with cell relative growth rate (RGR)
Judge cytotoxicity grade, its cytotoxicity of result is 1 grade, is qualified.
Embodiment three compositionss lixiviating solution is injected in the Intradermal of test rabbit, 24h, 48h and 72h after injection, perusal
Test rabbit all has no erythema, edema and necrosis phenomena, and this is to animal body no Intradermal irritant reaction.
With albino guinea-pig as animal subject, (GPMT) is tested using maximal dose, by the lixiviating solution note of embodiment three compositionss
Penetrate in Cavia porcelluss Intradermal, after carrying out Intradermal induction, stick in induction period not test (N.T.) position local and excited, divide in different time
The skin conditions at position Guan Cha not excited by Cavia porcelluss, with Magnusson and Kligman grade scale to each position and every of exciting
The skin erythema of one observing time and edema reaction are classified.Erythema and edema in result, and sensitization test (STT) is feminine gender, table
Bright embodiment three compositionss are to animal body no sensitivity response.
Using the sodium chloride lixiviating solution of embodiment three compositionss and vegetable oil lixiviating solution as test group, inject respectively with matched group
In Mice, and the general state in 4h, 24h, 48h, 72h observation and record test group and matched group, toxicity performance
With dead animal number.Result shows, immediate reaction, 4h, 24h, 48h, 72h observe avirulence symptoms, and body weight is not yet
Decline, the no Acute systemic toxicity reaction of embodiment three compositionss is described.
Example IV
Compositionss and preparation method thereof of prevention, treatment or suppression membrane disease a kind of are it is characterised in that described compositionss
Constituent content：
System stability：System is the viscous liquid of single stable, in 37 DEG C ± 2 DEG C of temperature, relative humidity 75% ± 5%
Under conditions of place the items quality index no significant change of 3 months test samples.
Suppression microorganism effect：According to《Disinfection technology standard》Detection method, stock solution act on 2min, to golden yellow Portugal
Grape coccus and escherichia coli suppression ratio ＞ 50.0%；Stock solution acts on 1min, to Candida albicans suppression ratio ＞ 50.0%.Experiment table
Bright have certain inhibitory action to oral cavity pathogen.
Biological assessment：
Cell toxicity test is carried out to example IV compositionss using mtt assay, has been come with cell relative growth rate (RGR)
Judge cytotoxicity grade, its cytotoxicity of result is 1 grade, is qualified.
Example IV compositionss lixiviating solution is injected in the Intradermal of test rabbit, 24h, 48h and 72h after injection, perusal
Test rabbit all has no erythema, edema and necrosis phenomena, and this is to animal body no Intradermal irritant reaction.
With albino guinea-pig as animal subject, (GPMT) is tested using maximal dose, by the lixiviating solution note of example IV compositionss
Penetrate in Cavia porcelluss Intradermal, after carrying out Intradermal induction, stick in induction period not test (N.T.) position local and excited, divide in different time
The skin conditions at position Guan Cha not excited by Cavia porcelluss, with Magnusson and Kligman grade scale to each position and every of exciting
The skin erythema of one observing time and edema reaction are classified.Erythema and edema in result, and sensitization test (STT) is feminine gender, table
Bright example IV compositionss are to animal body no sensitivity response.
Using the sodium chloride lixiviating solution of example IV compositionss and vegetable oil lixiviating solution as test group, inject respectively with matched group
In Mice, and the general state in 4h, 24h, 48h, 72h observation and record test group and matched group, toxicity performance
With dead animal number.Result shows, immediate reaction, 4h, 24h, 48h, 72h observe avirulence symptoms, and body weight is not yet
Decline, the no Acute systemic toxicity reaction of example IV compositionss is described.
Although, above, with general explanation and specific embodiment, the present invention has been made with detailed explanation, at this
On the basis of invention, can make some modifications or improvements, this will be apparent to those skilled in the art.Therefore, exist
Without departing from modifications or improvements on the basis of present invention spirit, belong to the scope of protection of present invention.
Claims (10)
1. a kind of prevention, treatment or suppression membrane disease compositionss and preparation method thereof it is characterised in that the component of described compositionss and
Weight percent content is：
Described membrane disease is belonging to ulcer, inflammation, traumatic damage or corrosivity and damages class disease or disease, including oral cavity
Ulcer (aphtha), herpes labialis, radiotherapy skin ulcer, reproductive tract ulcer, gastric mucosa ulcer, intestinal mucosa ulcer, actinic
The one of which such as keratosiss, behcet's syndrome, wart, halitosis, gingival swelling and pain or more than two kinds diseases or disease；
Described compositionss can be the form of solution, gel, gum, spray, gargarism, emulsion agent, ointment；
Described antimicrobial be glucose chlorhexidine, chlorhexidine acetate, benzalkonium chloride, benzethonium chloride, cetrimonium bromide, poly- six
Methylene guanidinesalt, cetylpyridinium chloride, brocide, parachlorometaxylenol, 2,4,4 '-three chloro- 2 '
- dihydroxy diphenyl ether, povidone iodine, phenol derivativess, glucoseoxidase, lysozyme, hydrogen peroxide, urea peroxide, wood
The one of which such as sugar alcohol or two kinds of things mixed above；
Described analgesics be cincaine, lignocaine, benzocaine, procaine, tetracaine, mepivacaine, cocaine,
The one of which such as dyclonine, benzyl alcohol, benzoic acid or two kinds of things mixed above；
Described bioadhesive polymer be Carbomer, hyetellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose,
Poly- sodium propionate, sodium alginate, carboxymethyl chitosan, hydroxypropyl chitosan, lactate shitosan, fucose, oligochitosan, thoroughly
The one of which such as bright matter acid, Aloe glue, tragacanth, xanthan gum, carrageenan, Polyvinylpyrrolidone or two kinds of things mixed above；
Described wetting agent is glycerol, Polyethylene Glycol, propylene glycol, erythritol, Sorbitol, Mannitol, maltose alcohol, glue
The one of which such as former albumen or two kinds of things mixed above；
Described pH adjusting agent be tartaric acid, malic acid, citric acid, 1-Hydroxy-1,2,3-propanetricarboxylic acid., phosphoric acid, lactic acid, sodium hydroxide, potassium hydroxide,
Triethanolamine, diisopropanolamine (DIPA), triisopropanolamine, trometamol, arginine, aminomethylpropanol, tetrahydroxypropyl second two
The one of which such as amine or two kinds of things mixed above；
Described correctivess are the one of which such as saccharin sodium, steviosin, cyclamate, Sucralose, Sorbitol, menthol, xylitol
Or two kinds of things mixed above；
Described emulsifying agent be Polysorbate, sodium laurylsulfate, glyceryl monostearate, polyoxyethylene groups castor oil derivative etc. its
In one or two or more kinds mixture；
Described auxiliary antimicrobial is imidazolidinyl urea, interior uride, iodopropynyl formate butyl, benzylalcohol, benzene first
The one of which such as acid, potassium sorbate, phenoxyethanol, parabenses or two kinds of things mixed above.
2. compositionss, antimicrobial component and the weight of a kind of prevention according to claim 1, treatment or suppression membrane disease
Degree 0.01%～10.0%.
3. compositionss, antimicrobial component and the weight of a kind of prevention according to claim 2, treatment or suppression membrane disease
Degree 0.1%～5.0%.
4. compositionss, analgesics component and the weight percent of a kind of prevention according to claim 1, treatment or suppression membrane disease
Than content 0.001%～5.0%.
5. compositionss, analgesics component and the weight percent of a kind of prevention according to claim 4, treatment or suppression membrane disease
Than content 0.1%～3.0%.
6. compositionss, bioadhesive polymer component and the weight of a kind of prevention according to claim 1, treatment or suppression membrane disease
Degree 0.01%～10.0%.
7. compositionss, bioadhesive polymer component and the weight of a kind of prevention according to claim 6, treatment or suppression membrane disease
Degree 0.1%～5.0%.
8. compositionss, wetting agent component and the weight percent of a kind of prevention according to claim 1, treatment or suppression membrane disease
Than content 0.1%～20.0%.
9. compositionss, wetting agent component and the weight percent of a kind of prevention according to claim 8, treatment or suppression membrane disease
Than content 0.5%～10.0%.
10. the compositionss of a kind of prevention according to claim 1, treatment or suppression membrane disease, component and percentage by weight contain
Measure and be：
Described membrane disease is including oral ulcer (aphtha), herpes labialis, radiotherapy skin ulcer, reproductive tract ulcer, gastric mucosa
The one of which or two such as ulcer, intestinal mucosa ulcer, actinic keratosises, behcet's syndrome, wart, halitosis, gingival swelling and pain
Plant above disease；
Described compositionss preferred form is solution, gel, gum, gargarism, emulsion agent, spray；
Described antimicrobial is glucose chlorhexidine, chlorhexidine acetate, benzalkonium chloride, benzethonium chloride, cetrimonium bromide, poly- six methylenes
Base guanidinesalt, cetylpyridinium chloride, brocide, parachlorometaxylenol, 2,4,4 '-three chloro- 2 '-hydroxyls
Yl diphenyl ether, povidone iodine, phenol derivativess, glucoseoxidase, lysozyme, hydrogen peroxide, urea peroxide, xylitol
Etc. one of which or two kinds of things mixed above；
The preferred cincaine of described analgesics, lignocaine, benzocaine, procaine, tetracaine, mepivacaine, benzene first
The one of which such as alcohol or two kinds of things mixed above；
The preferred Carbomer of described bioadhesive polymer, hyetellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, poly- sodium propionate,
Carboxymethyl chitosan, hydroxypropyl chitosan, lactate shitosan, oligochitosan, hyaluronic acid, Aloe glue, polyvinylpyrrolidine
The one of which such as ketone or two kinds of things mixed above；
Described wetting agent include glycerol, Polyethylene Glycol, propylene glycol, erythritol, Sorbitol, Mannitol, maltose alcohol,
The one of which such as collagen protein or two kinds of things mixed above；
Described pH adjusting agent includes tartaric acid, malic acid, citric acid, 1-Hydroxy-1,2,3-propanetricarboxylic acid., phosphoric acid, lactic acid, sodium hydroxide, hydrogen-oxygen
Change potassium, triethanolamine, diisopropanolamine (DIPA), triisopropanolamine, trometamol, arginine, aminomethylpropanol, tetrahydroxy third
The one of which such as base ethylenediamine or two kinds of things mixed above；
Described correctivess include saccharin sodium, steviosin, cyclamate, Sucralose, Sorbitol, menthol, xylitol etc. wherein
Plant or two kinds of things mixed above；
Described emulsifying agent be Polysorbate, sodium laurylsulfate, glyceryl monostearate, polyoxyethylene groups castor oil derivative etc. its
In one or two or more kinds mixture；
Described auxiliary antimicrobial includes imidazolidinyl urea, interior uride, iodopropynyl formate butyl, benzylalcohol, benzene
The one of which such as formic acid, potassium sorbate, phenoxyethanol, parabenses or two kinds of things mixed above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510514121.2A CN106466482A (en) | 2015-08-20 | 2015-08-20 | A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510514121.2A CN106466482A (en) | 2015-08-20 | 2015-08-20 | A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106466482A true CN106466482A (en) | 2017-03-01 |
Family
ID=58229006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510514121.2A Pending CN106466482A (en) | 2015-08-20 | 2015-08-20 | A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106466482A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519152A (en) * | 2017-09-07 | 2017-12-29 | 卢恕来 | A kind of stomatocace film and preparation method thereof |
| CN108014061A (en) * | 2017-12-27 | 2018-05-11 | 江苏博瑞思康生物科技有限公司 | A kind of oral nursing liquid of effectively bacteriostasis, and deodorization |
| CN108096429A (en) * | 2017-12-26 | 2018-06-01 | 庞庆华 | A kind of mouth sprays for alleviating oral peculiar smell and preparation method thereof |
| CN108126128A (en) * | 2018-02-02 | 2018-06-08 | 上海哈美实业发展有限公司 | A kind of oral antimicrobial gelling agent and preparation method thereof |
| CN109431998A (en) * | 2018-12-04 | 2019-03-08 | 山西瑞博隆生物科技有限公司 | A kind of benzalkonium chloride compound micro emulsion and preparation method thereof |
| RU2699560C1 (en) * | 2019-04-09 | 2019-09-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Dental gel with a phytopeloid composition |
| RU2713943C1 (en) * | 2019-10-28 | 2020-02-11 | Александр Ливиевич Ураков | Gel for children's skin |
| CN111329881A (en) * | 2020-03-27 | 2020-06-26 | 中国医学科学院北京协和医院 | Oral ulcer film and preparation method and application thereof |
| CN111773182A (en) * | 2020-08-24 | 2020-10-16 | 山东大学 | Compound preparation for preventing virus infection and preparation/use method and application thereof |
| RU2749713C1 (en) * | 2020-07-29 | 2021-06-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Dental gel |
| EP4082528A1 (en) * | 2021-04-30 | 2022-11-02 | GSK Consumer Healthcare SARL | Liquid spray formulation |
-
2015
- 2015-08-20 CN CN201510514121.2A patent/CN106466482A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519152A (en) * | 2017-09-07 | 2017-12-29 | 卢恕来 | A kind of stomatocace film and preparation method thereof |
| CN108096429A (en) * | 2017-12-26 | 2018-06-01 | 庞庆华 | A kind of mouth sprays for alleviating oral peculiar smell and preparation method thereof |
| CN108014061A (en) * | 2017-12-27 | 2018-05-11 | 江苏博瑞思康生物科技有限公司 | A kind of oral nursing liquid of effectively bacteriostasis, and deodorization |
| CN108126128A (en) * | 2018-02-02 | 2018-06-08 | 上海哈美实业发展有限公司 | A kind of oral antimicrobial gelling agent and preparation method thereof |
| CN109431998A (en) * | 2018-12-04 | 2019-03-08 | 山西瑞博隆生物科技有限公司 | A kind of benzalkonium chloride compound micro emulsion and preparation method thereof |
| RU2699560C1 (en) * | 2019-04-09 | 2019-09-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Dental gel with a phytopeloid composition |
| RU2713943C1 (en) * | 2019-10-28 | 2020-02-11 | Александр Ливиевич Ураков | Gel for children's skin |
| CN111329881A (en) * | 2020-03-27 | 2020-06-26 | 中国医学科学院北京协和医院 | Oral ulcer film and preparation method and application thereof |
| RU2749713C1 (en) * | 2020-07-29 | 2021-06-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Dental gel |
| CN111773182A (en) * | 2020-08-24 | 2020-10-16 | 山东大学 | Compound preparation for preventing virus infection and preparation/use method and application thereof |
| CN111773182B (en) * | 2020-08-24 | 2022-08-02 | 山东大学 | Compound preparation for preventing virus infection and preparation/use method and application thereof |
| EP4082528A1 (en) * | 2021-04-30 | 2022-11-02 | GSK Consumer Healthcare SARL | Liquid spray formulation |
| WO2022229358A1 (en) * | 2021-04-30 | 2022-11-03 | Gsk Consumer Healthcare Sarl | Liquid spray formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106466482A (en) | A kind of compositionss of prevention, treatment or suppression membrane disease and preparation method thereof | |
| ES2655876T3 (en) | Trigonella foenum-graecum extract | |
| RU2640301C2 (en) | Antiseptic composition intended for application in oral cavity, for treatment of oral mucositis | |
| EP3035915B1 (en) | Composition, especially in the form of a lubricant gel comprising a local anaesthetic and polyhexanide | |
| RU2571063C2 (en) | Polysaccharide of tamarind seed for application in treatment of microbial infections | |
| BR112020002106A2 (en) | gel comprising chlorhexidine | |
| US20230113715A1 (en) | Compositions and methods for treatment of skin infections | |
| CN106310266A (en) | Composition for preventing or treating mucous membrane diseases and preparation method thereof | |
| CN109568249A (en) | A kind of women secret maintenance bacteriostatic gel and its preparation method and application | |
| WO2018076856A1 (en) | Eugenol oral ulcer membrane and preparation method therefor | |
| AT15430U1 (en) | Dental agent based on hyaluronan and octenidine dihydrochloride | |
| US12064404B2 (en) | Topical formulations and treatments | |
| CN101559077A (en) | Gargle for relieving pain for oral inflammation disease | |
| CN104840958A (en) | Artificial mucosa composition as well as preparation method and application thereof | |
| CN111956664A (en) | Composition for pets and application thereof | |
| CN105560074A (en) | Toothpaste | |
| KR20000069990A (en) | Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and a preparation containing dichlorobenzyl alcohol | |
| CN104906132B (en) | A kind of plaster for preventing and treating lamb stomatitis | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| DE102012000430B4 (en) | Composition for topical use I. | |
| Blea et al. | How to evaluate and treat ulceration of the glosso-epiglottic fold (subepiglottic area) in the standing horse. | |
| CN115990128A (en) | Oral care composition | |
| RU2360666C2 (en) | Complex antiseptic for treatment of animals with purulent, purulent-necrotic and purulent-putrefactive lesions of tissues | |
| CN118370719A (en) | Antibacterial liquid for private parts and preparation method thereof | |
| CN118021783A (en) | Compound antipyretic analgesic preparation for animals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170301 |
|
| WD01 | Invention patent application deemed withdrawn after publication |